Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
SOTIO Biotech logo — Shaping the future of cancer immunotherapies by translating...

SOTIO Biotech

Shaping the future of cancer immunotherapies by translating compelling science into patient benefit.

Founded 2010 Czech Republic Czech Republic 229 employees Venture round Total: $280.30M Biotechnology, Health Care +1

General Information

Company Name SOTIO Biotech
Founded Year 2010
Location Czech Republic Czech Republic
Employees 229
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with SOTIO Biotech. To contact SOTIO Biotech, visit sotio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does SOTIO Biotech compare?

A PDF of SOTIO Biotech and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting SOTIO Biotech soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About SOTIO Biotech

SOTIO Biotech is a Czech Republic-based biotechnology company, established in 2010. The company's slogan "Shaping the future of cancer immunotherapies by translating compelling science into patient benefit" reflects its core mission. SOTIO Biotech is focused on translating scientific breakthroughs into tangible patient benefits within the healthcare industry. The company's recent milestones include a significant €280.00M Venture Round investment secured on 02 December 2021, with the investment coming from its parent company, the PPF Group. The company's robust clinical pipeline features cutting-edge therapeutic approaches, including a next-generation PD-1-inhibiting cytokine, proprietary technology designed to enhance the efficacy of CAR T therapies, and a new generation of potent and stable antibody-drug conjugates (ADCs). These innovative advancements position SOTIO Biotech at the forefront of the evolving landscape of cancer immunotherapies, promising potential breakthroughs in the treatment of this pervasive disease. SOTIO Biotech's strategic focus on leveraging compelling science to drive patient benefits, combined with substantial financial backing from the PPF Group, positions the company as a key player in the biotechnology and healthcare sectors. With a clear dedication to innovation and a strong emphasis on clinical advancement, SOTIO Biotech stands poised to make significant strides in cancer treatment and potentially reshape the future of immunotherapies.

Business keywords: Cancer immunotherapies, Biotech, Clinical pipeline, PD-1-inhibiting cytokine, CAR T therapies, Antibody-drug conjugates, PPF Group, Research & development, Collaborations, In-licensing, Investments, Mergers, Active cellular immunotherapy, Dendritic cells, Autoimmune diseases

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round €280.00M 1
PPF Group
PPF Group
02 Dec 2021
Venture Round $300.00K -
06 Jun 2017

SOTIO Biotech Alternatives & Competitors

View All Alternatives
SOTIO Biotech vs
Antharis Therapeutics, Inc.
Antharis Therapeutics, Inc. United States

Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting-edge trea...

18 employees
Biopharma, Biotechnology
Compare SOTIO Biotech vs Antharis Therapeutics, Inc.
SOTIO Biotech vs
Prescient Therapeutics
Prescient Therapeutics Australia

A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...

Post-IPO Equity
14 employees
Biopharma, Biotechnology
Compare SOTIO Biotech vs Prescient Therapeutics
SOTIO Biotech vs
Celularity Inc.
Celularity Inc. United States

A next-gen Biotech company creating off-the-shelf cellular medicines for Cancer, Infectious, and Deg...

Post-IPO Equity
171 employees
Biotechnology, Health Care
View all alternatives

FAQ About SOTIO Biotech

Shaping the future of cancer immunotherapies by translating compelling science into patient benefit.
SOTIO Biotech was founded in 2010.
SOTIO Biotech is headquartered in Czech Republic.
SOTIO Biotech operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Cancer immunotherapies, Biotech, Clinical pipeline and PD-1-inhibiting cytokine.
SOTIO Biotech has approximately 229 employees.
SOTIO Biotech has completed 2 funding rounds, raising a total of $280.30M. The latest funding stage is Venture round.
Top alternatives and competitors to SOTIO Biotech include Antharis Therapeutics, Inc., Prescient Therapeutics, Celularity Inc., VBL Therapeutics (Nasdaq:VBLT), Sensei Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SOTIO Biotech and Antharis Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for SOTIO Biotech, https://bouncewatch.com/company/sotio-biotech, updated 29 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout